The Effect of Topical Bevacizumab on Corneal Neovascularization

Sang Woo Kim, Byung Jin Ha, Eung Kweon Kim, Hungwon Tchah, Tae im Kim

Research output: Contribution to journalArticlepeer-review

195 Citations (Scopus)


Purpose: To examine the effect of topical bevacizumab on corneal neovascularization (NV) over a period of 3 months. Design: Prospective, nonrandomized, masked observational case series. Participants: Ten eyes of 7 patients with corneal NV. Methods: Patients received topical bevacizumab (1.25%) twice daily. Ophthalmic evaluations included visual acuity, slit-lamp examination, and tonometry. Main Outcome Measures: Corneal NV and changes in ophthalmic evaluations. Results: Decreased corneal NV was noted in 7 of 10 eyes, usually within 1 month of treatment. Epitheliopathy (epithelial defect, epithelial erosion) was observed in 6 of 10 eyes, 1 resulting in corneal thinning. Adverse effects generally appeared during the second month of treatment. Conclusions: Topical application of bevacizumab was effective in reducing corneal NV within the first month. However, by the second month there was an increased risk of adverse effects.

Original languageEnglish
Pages (from-to)e33-e38
Issue number6
Publication statusPublished - 2008 Jun

Bibliographical note

Funding Information:
This study was supported by Korean Research Foundation grant 2006-KRF-531-E00121.

All Science Journal Classification (ASJC) codes

  • Ophthalmology


Dive into the research topics of 'The Effect of Topical Bevacizumab on Corneal Neovascularization'. Together they form a unique fingerprint.

Cite this